<DOC>
	<DOCNO>NCT00002754</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . PURPOSE : Phase I/II trial determine effectiveness monoclonal antibody therapy treat patient primary metastatic melanoma brain tumor .</brief_summary>
	<brief_title>Monoclonal Antibody Therapy Treating Patients With Primary Metastatic Melanoma Brain Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxicity maximum tolerate dose iodine-131-labeled monoclonal antibody fragment ME1-14 F ( ab ' ) 2 administer intracystically patient recurrent newly diagnose primary metastatic malignant melanoma brain tumor . II . Identify objective therapeutic response treatment . OUTLINE : All patient receive fix dose monoclonal antibody fragment ME1-14 F ( ab ' ) 2 via intralesional catheter ; cohort 3-6 patient receive escalate dos isotope conjugate antibody maximum tolerate dose determine . Patients newly diagnose disease entry may receive additional therapy external-beam radiotherapy begin 4 month radioimmunotherapy ( sooner disease progression occur ) . Patients recurrent disease entry follow without therapy least 4 month radioimmunotherapy ; alternative therapy may offer upon progression . All patient follow 4 , 8 , 16 , 24 week treatment , every 12 week 1 year . PROJECTED ACCRUAL : Three six patient enter dose study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary metastatic malignant melanoma OR Histologically confirm supratentorial malignant brain tumor Newly diagnose recurrent primary metastatic tumor Eligible primary histology , include limited : Glioblastoma multiforme Mixed anaplastic glioma Anaplastic astrocytoma Other astrocytoma Gliosarcoma Anaplastic oligodendroglioma The follow exclude : Diffusely infiltrate tumor Multifocal tumor Infratentorial tumor Subependymal spread No measurable enhance lesion extend 1 cm beyond margin surgical cavity contrastenhanced CT MRI perform within 72 hour resection Intralesional catheter place resection Patency catheter demonstrate radiolabeled albumin flow Reactivity neoplastic cell intact Me114 IgG2a Me114 F ( ab ' ) 2 demonstrated immunohistology polyclonal rabbit antibody monoclonal mouse antibody PATIENT CHARACTERISTICS : Age : 3 Performance status : Karnofsky 50 % 100 % Hematopoietic : Absolute neutrophil count great 1,000/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin le 1.5 mg/dL AST le 1.5 time normal Alkaline phosphatase less 1.5 time normal Renal : Creatinine le 1.2 mg/dL Other : Not pregnant PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 6 week since antineoplastic chemotherapy unless unequivocal tumor progression Endocrine therapy : Concurrent corticosteroid allow low possible dose stable least 10 day prior entry Radiotherapy : At least 3 month since radiotherapy site measurable disease within nervous system unless unequivocal tumor progression Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>tumor metastatic brain</keyword>
	<keyword>childhood high-grade cerebral astrocytoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>recurrent childhood cerebral astrocytoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>